Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions Scinai files an application for Euro 12 million grant to fund the next stage of development Pincell’s monoclonal antibody,...
Two pre-clinical studies carried out by leading dermatologist Dr. Riichiro Abe, Professor and Chair of Dermatology at Niigata University, indicate that PC111 monoclonal antibody can ease Stevens-Johnson Syndrome by eliminating excess of circulating Fas ligand.Severe...
Proprietary transgenic mouse produces human form of FasL protein May 4, 2023 – MILAN – PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two...
The biotechnology company has established a promising in-vivo platform for the development of its lead therapy, a monoclonal antibody that stops blistering in chronic skin conditions without suppressing the immune system. January 19, 2023 – MILAN –...
The nominations follow a successful seed funding led by Sofinnova Partners MILAN, Italy – May 6, 2020 – PinCell, a biotechnology company developing novel therapies for rare dermatological diseases, announced today the appointment of Gabriella Camboni,...
Il prof. Pincelli e la dottoressa Marconi hanno creato un farmaco contro il pemfigo che non deprime il sistema immunitario di Davide Berti – Gazzetta di Modena – 22.06.2015 – Ricerca, speranza e nuova cura. Sono queste le parole d’ordine. Due medici...
